Tandem Guides 2026 U.S. Sales to $730M-$745M
TNDM sits 65% above its 52-week low of $12.26.
Summary
Tandem put a 2026 U.S. sales target of roughly $730 million to $745 million on the table, its first formal top-line outlook for next year, alongside a 2026 international sales outlook of approximately $335 million to $340 million. For scale, Q2 2026 sales were $254.6 million, up 6%, so the guide implies continued single-digit-to-low-double-digit growth rather than a sharp reacceleration. The range lands alongside this evening's Q3 report showing a 10-cent per-share loss and the naming of Jeannette Bankes as President and CEO, so the new chief is inheriting a modest growth plan. Bankes will succeed John Sheridan, who will retire at the end of 2026, and she recently served as President and CEO of GE HealthCare's Patient Care Solutions segment. The width of the range leaves room for either outcome; the midpoint is the number to anchor on.
At the time of this announcement, TNDM was trading at $20.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.26 to $29.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.